A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of ibandronate (Bondronat), administered
intravenously (IV) or orally (PO), in participants with malignant bone disease and moderate
to severe pain. Participants will be randomized to receive ibandronate either as a 6-mg IV
infusion every 3 to 4 weeks or a 50-mg tablet PO daily. Pain response and Karnofsky
Performance Index (KPI) will be measured at intervals throughout the study. The anticipated
time on study treatment is 4 months and the target sample size is 150 individuals.